Destiny Pharma welcomes the US government’s healthcare reform for novel antibacterial drug payments which include an alternative pathway for New Technology Add-On Payments (NTAPs) which increases the value of these payments to 75% for Qualified Infectious Disease Products (QIDPs). This, combined with the UK government 2019 initiative, represents tangible progress to incentivise and reward the developers of novel anti-infectives such as Destiny Pharma.